ECTRIMS SPECIAL REPORT

The recently concluded European Committee on Treatment and Research in MS (ECTRIMS) annual meeting presented a number of new approaches for evaluating the efficacy of high-efficacy disease-modifying therapies. Read More

The European Committee for Treatment and Research in MS (ECTRIMS) annual meeting presented new data that helped to clarify the mode of action of anti-CD20 agents and address some safety issues that have arisen during the COVID-19 pandemic. Read More

A new study has found that a high proportion of MS patients with no evidence of disease activity (NEDA) in the first two years of treatment will experience relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) (Prosperini et al. Neurol Neuroimmunol Neuroinflamm 2021;8:e1059). Read More

37^th Congress of the European Committee for Treatment and Research in Multiple Sclerosis – October 13-15, 2021

The following summarizes some of the highlights from Day 3 of ECTRIMS 2021.

October 14 Edition
October 13 Edition Read More